ArticleScientific reports2016
A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Systematic Worldwide Review on the Performance of Non-Invasive Exhalation-Based Methods for the Diagnosis of Liver Fibrosis.International journal of environmental research and public health · 2026Pooled it
- Breath volatile profiling reveals a diagnostic signature of MASLD in children.medRxiv : the preprint server for health sciences · 2026Article
- Breath-Based Diagnostics in Liver Diseases: Dynamic Assessment of Hepatic Metabolic Reserve and Liver Fibrosis.Gastro hep advances · 2026Review
- Systematic comparison of methods for offline breath sampling.Analytical and bioanalytical chemistry · 2025Article
- Non-Invasive Biomarkers and Breath Tests for Diagnosis and Monitoring of Chronic Liver Diseases.Diagnostics (Basel, Switzerland) · 2024Review
- Prospect and Challenges of Volatile Organic Compound Breath Testing in Non-Cancer Gastrointestinal Disorders.Biomedicines · 2024Review
- Alteration of Plasma Indoles in Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Exogenous Volatile Organic Compound (EVOCBiomedicines · 2023Article
- Characterization of Salivary and Plasma Metabolites as Biomarkers for HCC: A Pilot Study.Cancers · 2023Article
- Breath BiopsyJournal of clinical and translational hepatology · 2023Article
- An ultrasensitive isoprene gas sensor based on the InRSC advances · 2023Article
- Review
- Skin Autofluorescence Measurement as Initial Assessment of Hepatic Parenchyma Quality in Patients Undergoing Liver Resection.Journal of clinical medicine · 2022Article
- pyAIR-A New Software Tool for Breathomics Applications-Searching for Markers in TD-GC-HRMS Analysis.Molecules (Basel, Switzerland) · 2022Article
- An Experimental Apparatus for E-Nose Breath Analysis in Respiratory Failure Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Volatolomics in healthcare and its advanced detection technology.Nano research · 2022Review
- A deep learning approach for detecting liver cirrhosis from volatolomic analysis of exhaled breath.Frontiers in medicine · 2022Article
- Volatile organic compounds: A proinflammatory activator in autoimmune diseases.Frontiers in immunology · 2022Review
- Hyphenated Mass Spectrometry versus Real-Time Mass Spectrometry Techniques for the Detection of Volatile Compounds from the Human Body.Molecules (Basel, Switzerland) · 2021Review
- Breath-Taking Perspectives and Preliminary Data toward Early Detection of Chronic Liver Diseases.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of liver cirrhosis may prevent progression and development of complications. Liver biopsy is the current standard, but is invasive and associated with morbidity. We aimed to identify exhaled volatiles within a heterogeneous group of chronic liver disease (CLD) patients that discriminates those with compensated cirrhosis (CIR) from those without cirrhosis, and compare this with serological markers. Breath samples were collected from 87 CLD and 34 CIR patients. Volatiles in exhaled air were measured by gas chromatography mass spectrometry. Discriminant Analysis was performed to identify the optimal panel of serological markers and VOCs for classifying our patients using a random training set of 27 CIR and 27 CLD patients. Two randomly selected independent internal validation sets and permutation test were used to validate the model. 5 serological markers were found to distinguish CIR and CLD patients with a sensitivity of 0.71 and specificity of 0.84. A set of 11 volatiles discriminated CIR from CLD patients with sensitivity of 0.83 and specificity of 0.87. Combining both did not further improve accuracy. A specific exhaled volatile profile can predict the presence of compensated cirrhosis among CLD patients with a higher accuracy than serological markers and can aid in reducing liver biopsies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.